Contact
searchSearch
HMP Global
Login

Myelofibrosis News

Conference Coverage
Machine Learning Model Beneficial in Predicting Overall Survival in Patients With Myelofibrosis
01/31/2023
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study indicated that the use of a simple machine learning model known as the AIPSS-MF model was associated with an elevated rate of accuracy with regard to predicting OS in patients with primary and secondary MF,...
Findings from a recent study...
01/31/2023
Journal of Clinical Pathways
News
Retrospective Study Confirms the Palliative Role of JAK2 Inhibitors in Treatment of Myelofibrosis and Beneficial Effect of ASCT on Survival
01/31/2023
A retrospective study proposed the value of specific pre-treatment variables in recognizing long-lived patients with myelofibrosis receiving Janus kinase 2 inhibitors and also validated recent findings regarding the beneficial effect on...
A retrospective study proposed the value of specific pre-treatment variables in recognizing long-lived patients with myelofibrosis receiving Janus kinase 2 inhibitors and also validated recent findings regarding the beneficial effect on...
A retrospective study proposed...
01/31/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
News
Momelotinib Superior to Danazol in Symptomatic and Anemic Myelofibrosis Patients Previously Treated With JAK Inhibitor
11/17/2022
Momelotinib improved symptom responses, transfusion requirements, and spleen responses for symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol, according to the phase 3 MOMENTUM...
Momelotinib improved symptom responses, transfusion requirements, and spleen responses for symptomatic and anemic myelofibrosis patients previously treated with a JAK inhibitor when compared with danazol, according to the phase 3 MOMENTUM...
Momelotinib improved symptom...
11/17/2022
Oncology
News
Momelotinib Demonstrated Superior Responses, Survival to Danazol in Patients With Thrombocytopenic Myelofibrosis
10/18/2022
Momelotinib was superior to danazol in symptomatic, anemic, and thrombocytopenic myelofibrosis patients for symptom responses, transfusion requirements, and spleen responses, according to a phase 3 trial.
Momelotinib was superior to danazol in symptomatic, anemic, and thrombocytopenic myelofibrosis patients for symptom responses, transfusion requirements, and spleen responses, according to a phase 3 trial.
Momelotinib was superior to...
10/18/2022
Oncology
News
Jaktinib Improves Clinical Symptoms in JAK Inhibitor-Naïve Patients With Myelofibrosis
09/20/2022
Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.
Jaktinib reduces spleen volume and improves anemia and other clinical symptoms with acceptable tolerability in JAK inhibitor-naïve patients with myelofibrosis, according to results from a phase 2 trial.
Jaktinib reduces spleen volume...
09/20/2022
Oncology
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use